Clinical Trials Browser

Lymphoma, B-Cell × CTLA-4 Antigen × Clear all

NCT03017820 2025-10-08

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT01729806 2018-04-11

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Phase 1 Completed

32 enrolled

Lymphoid

Lymphoma, B-Cell